Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy

@article{Ning2017DevelopmentO1,
  title={Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy},
  author={Xiaohui Ning and Y. Yang and H. Deng and Qihao Zhang and S. Zhang},
  journal={Steroids},
  year={2017},
  volume={121},
  pages={10-16}
}
  • Xiaohui Ning, Y. Yang, +2 authors S. Zhang
  • Published 2017
  • Biology, Medicine
  • Steroids
  • 17β-Hydroxysteroid dehydrogenase type 3 (17β-HSD3) is expressed almost exclusively in the testes and specifically converts the weak androgenic androstenedione to active testosterone (T) in the presence of NADPH. Additionally, studies have demonstrated that 17β-HSD3 is over-expressed in hormone-dependent prostate cancer. T, which interacts with the androgen receptor (AR), eventually stimulates the growth of prostate cancer cells. Defects in T synthesis or action impair the development of the… CONTINUE READING
    2 Citations

    References

    SHOWING 1-10 OF 47 REFERENCES
    17β-Hydroxysteroid dehydrogenase inhibitors: a patent review
    • D. Poirier
    • Biology, Medicine
    • Expert opinion on therapeutic patents
    • 2010
    • 70